Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

3 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Treatment - Gynecologic Oncology Group Surgical Status Form - 2918053v1.0 - Gynecologic Oncology Group Surgical Status Form

- 09-01-15 - 1 Formulier, 7 Itemgroepen, 28 Data-elementen, 1 Taal
Itemgroepen: HEADER MODULE, SURGICAL INFORMATION, FIRST SURGICAL PROCEDURE, SECOND SURGICAL PROCEDURE, THIRD SURGICAL PROCEDURE, FOURTH SURGICAL PROCEDURE, Comments
Gynecologic Oncology Group Surgical Status Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6E5EDF6F-8B38-E23E-E040-BB89AD435A10

Fallopian Tube Cancer NCT00951496 Treatment - Gynecologic Oncology Group Surgical Status Form - 2305792v3.0 - Gynecologic Oncology Group Surgical Status Form

- 09-01-15 - 1 Formulier, 7 Itemgroepen, 28 Data-elementen, 1 Taal
Itemgroepen: HEADER MODULE, SURGICAL INFORMATION, FIRST SURGICAL PROCEDURE, SECOND SURGICAL PROCEDURE, THIRD SURGICAL PROCEDURE, FOURTH SURGICAL PROCEDURE, Comments
Gynecologic Oncology Group Surgical Status Form Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F17BE4C4-06A3-1816-E034-0003BA3F9857

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Screening - Prior Ovarian Cancer Treatment; Laboratory Tests; Lesion Assessment Record

- 23-08-19 - 1 Formulier, 13 Itemgroepen, 48 Data-elementen, 1 Taal
Itemgroepen: Administrative, Prior Ovarian Cancer Treatment - Chemotherapy, Has the patient received radiotherapy?, Prior Ovarian Cancer Treatment - Radiotherapy , Has the patient received prior cancer-related surgery?, Prior Ovarian Cancer Treatment - Surgical Treatment , Has the patient received other cancer-related treatments?, Other Cancer Related Treatments, Laboratory Tests (within 7 days prior to Day 1) - Haematology, Laboratory Tests (within 7 days prior to Day 1) - Haematology , Laboratory Tests (within 7 days prior to Day 1) - Chemistry, Laboratory Tests (within 7 days prior to Day 1) - Chemistry , Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial